Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract 1651: In vitro and in vivo profile of the preclinical candidate and MPS1 kinase inhibitor CCT289346

Cancer Res (2018) 78 (13_Supplement): 1651.

https://doi.org/10.1158/1538-7445.AM2018-1651

Published: 01 July 2018

View article titled, Abstract 1651: In vitro and in vivo profile of the preclinical candidate and MPS1 kinase inhibitor CCT289346

Journal Articles

Abstract 4036: Induction of detrimental aneuploidy in basal breast cancer cells treated by MPS1 inhibitors in combination with paclitaxel

Cancer Res (2017) 77 (13_Supplement): 4036.

https://doi.org/10.1158/1538-7445.AM2017-4036

Published: 01 July 2017

View article titled, Abstract 4036: Induction of detrimental aneuploidy in basal breast cancer cells treated by MPS1 inhibitors in combination with paclitaxel

Journal Articles

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance

Orli Yogev, Karen Barker, Arti Sikka, Gilberto S. Almeida, Albert Hallsworth, Laura M. Smith, Yann Jamin, Ruth Ruddle, Alexander Koers, Hannah T. Webber, Florence I. Raynaud, Sergey Popov, Chris Jones, Kevin Petrie, Simon P. Robinson, Hector C. Keun, Louis Chesler

Cancer Res (2016) 76 (10): 3025–3035.

https://doi.org/10.1158/0008-5472.CAN-15-1939

Published: 12 May 2016

View article titled, p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance

Includes: Supplementary data

Journal Articles

Abstract 3642: Structure enabled design of inhibitors of the mitotic kinase MPS1

Paolo Innocenti, Hannah Woodward, Kwai_Ming J. Cheung, Sébastien Naud, Savade Solanki, Isaac M. Westwood, Amir Faisal, Angela Hayes, Jessica Schmitt, Ross Baker, Berry Matijssen, Rosemary Burke, Suzanne A. Eccles, Florence I. Raynaud, Spiros Linardopoulos, Julian Blagg, Rob L M van Montfort, Swen Hoelder

Cancer Res (2015) 75 (15_Supplement): 3642.

https://doi.org/10.1158/1538-7445.AM2015-3642

Published: 01 August 2015

View article titled, Abstract 3642: Structure enabled design of inhibitors of the mitotic kinase MPS1

Journal Articles

Abstract 3517: Changes in plasma components of β-oxidation as a pharmacodynamic (PD) biomarker of PI3K inhibition by GDC-0941, a potent, pan-inhibitor of Class I phosphatidyl-inositol-3-kinase (PI3K).

Joo Ern Ang, Rupinder Pandher, Yasmin Asad, Alan Henley, Melanie Valenti, Gary Box, Alexis de haven Brandon, Suzan Eccles, Paul Workman, Johann S. de Bono, Florence I. Raynaud

Cancer Res (2013) 73 (8_Supplement): 3517.

https://doi.org/10.1158/1538-7445.AM2013-3517

Published: 15 April 2013

View article titled, Abstract 3517: Changes in plasma components of β-oxidation as a pharmacodynamic (PD) biomarker of PI3K inhibition by GDC-0941, a potent, pan-inhibitor of Class I phosphatidyl-inositol-3-kinase (PI3K).

Journal Articles

Abstract 1817: Characterisation of CCT251455, a novel, selective and highly potent Mps1 kinase inhibitor

Cancer Res (2012) 72 (8_Supplement): 1817.

https://doi.org/10.1158/1538-7445.AM2012-1817

Published: 15 April 2012

View article titled, Abstract 1817: Characterisation of CCT251455, a novel, selective and highly potent Mps1 kinase inhibitor

Journal Articles

Abstract 928: The novel clinical candidate AT13148 is an oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity and demonstrates a mechanism of action distinct from AKT inhibitors

Cancer Res (2012) 72 (8_Supplement): 928.

https://doi.org/10.1158/1538-7445.AM2012-928

Published: 15 April 2012

View article titled, Abstract 928: The novel clinical candidate AT13148 is an oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity and demonstrates a mechanism of action distinct from AKT inhibitors

Journal Articles

Abstract 3554: CCT137690, a dual inhibitor of Aurora and FLT3 kinases, sensitizes FLT3-ITD positive acute myeloid leukemia and overcomes resistance to selective FLT3-inhibition

Andrew S. Moore, Amir Faisal, Vassilios Bavetsias, Chongbo Sun, Butrus Atrash, Melanie Valenti, Alexis de Haven Brandon, Sian Avery, David Gonzalez de Castro, Florence I. Raynaud, Paul Workman, Andrew DJ Pearson, Julian Blagg, Suzanne A. Eccles, Spiros Linardopoulos

Cancer Res (2011) 71 (8_Supplement): 3554.

https://doi.org/10.1158/1538-7445.AM2011-3554

Published: 15 April 2011

View article titled, Abstract 3554: CCT137690, a dual inhibitor of Aurora and FLT3 kinases, sensitizes FLT3-ITD positive acute myeloid leukemia and overcomes resistance to selective FLT3-inhibition

Journal Articles

The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy

Nada M.S. Al-Saffar, L. Elizabeth Jackson, Florence I. Raynaud, Paul A. Clarke, Ana Ramírez de Molina, Juan C. Lacal, Paul Workman, Martin O. Leach

Cancer Res (2010) 70 (13): 5507–5517.

https://doi.org/10.1158/0008-5472.CAN-09-4476

Published: 30 June 2010

View article titled, The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy

Includes: Supplementary data

Journal Articles

Abstract 3518: Preclinical pharmacology of the novel, potent & selective CHK1 inhibitor SAR-020106

Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis De Haven Brandon, Gary Box, G Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, David H. Williams, John C. Reader, Ian Collins, Michelle D. Garrett

Cancer Res (2010) 70 (8_Supplement): 3518.

https://doi.org/10.1158/1538-7445.AM10-3518

Published: 15 April 2010

View article titled, Abstract 3518: Preclinical pharmacology of the novel, potent & selective CHK1 inhibitor SAR-020106

Journal Articles

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

Paul Workman, Paul A. Clarke, Florence I. Raynaud, Rob L.M. van Montfort

Cancer Res (2010) 70 (6): 2146–2157.

https://doi.org/10.1158/0008-5472.CAN-09-4355

Published: 14 March 2010

View article titled, Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

Includes: Multimedia, Supplementary data

Journal Articles

NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

Cancer Res (2008) 68 (8): 2850–2860.

https://doi.org/10.1158/0008-5472.CAN-07-5256

Published: 15 April 2008

View article titled, NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

Includes: Supplementary data

Journal Articles

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Cancer Res (2007) 67 (12): 5840–5850.

https://doi.org/10.1158/0008-5472.CAN-06-4615

Published: 15 June 2007

View article titled, Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Includes: Supplementary data

Journal Articles

Phase I study of SR4554 as a non-invasive probe of tumor hypoxia detected by magnetic resonance spectroscopy

Chooi P. Lee, Geoffrey S. Payne, Alain Oregioni, Ruth R. Ruddle, Florence I. Raynaud, David A. Eaton, Kathryn Cross, Michael Tracy, James P. McNamara, Martin O. Leach, Ian R. Judson, Paul Workman

Cancer Res (2006) 66 (8_Supplement): 232.

Published: 15 April 2006

View article titled, Phase I study of SR4554 as a non-invasive probe of tumor hypoxia detected by magnetic resonance spectroscopy

Journal Articles

SR4554 as a non-invasive probe of tumor hypoxia detected by Magnetic Resonance Spectroscopy: Update of a Phase I Trial

Chooi P. Lee, Geoffrey S. Payne, Ruth R. Ruddle, Florence I. Raynaud, Siew K. Tan, Maeli J. Campbell, Michael Tracy, James P. McNamara, Martin O. Leach, Ian R. Judson, Paul Workman

Cancer Res (2005) 65 (9_Supplement): 897.

Published: 01 May 2005

View article titled, SR4554 as a non-invasive probe of tumor hypoxia detected by Magnetic Resonance Spectroscopy: Update of a Phase I Trial

NARROW

Abstract 1651: In vitro and in vivo profile of the preclinical candidate and MPS1 kinase inhibitor CCT289346

Abstract 4036: Induction of detrimental aneuploidy in basal breast cancer cells treated by MPS1 inhibitors in combination with paclitaxel

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance

Abstract 3642: Structure enabled design of inhibitors of the mitotic kinase MPS1

Abstract 3517: Changes in plasma components of β-oxidation as a pharmacodynamic (PD) biomarker of PI3K inhibition by GDC-0941, a potent, pan-inhibitor of Class I phosphatidyl-inositol-3-kinase (PI3K).

Abstract 1817: Characterisation of CCT251455, a novel, selective and highly potent Mps1 kinase inhibitor

Abstract 928: The novel clinical candidate AT13148 is an oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity and demonstrates a mechanism of action distinct from AKT inhibitors

Abstract 3554: CCT137690, a dual inhibitor of Aurora and FLT3 kinases, sensitizes FLT3-ITD positive acute myeloid leukemia and overcomes resistance to selective FLT3-inhibition

The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy

Abstract 3518: Preclinical pharmacology of the novel, potent & selective CHK1 inhibitor SAR-020106

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Phase I study of SR4554 as a non-invasive probe of tumor hypoxia detected by magnetic resonance spectroscopy

SR4554 as a non-invasive probe of tumor hypoxia detected by Magnetic Resonance Spectroscopy: Update of a Phase I Trial

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only